Hookipa Pharma (HOOK) Competitors $2.49 -0.09 (-3.49%) (As of 11:43 AM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends HOOK vs. IMUX, CNTX, DERM, PYXS, MNOV, ANRO, MNPR, LPTX, RANI, and ASMBShould you be buying Hookipa Pharma stock or one of its competitors? The main competitors of Hookipa Pharma include Immunic (IMUX), Context Therapeutics (CNTX), Journey Medical (DERM), Pyxis Oncology (PYXS), MediciNova (MNOV), Alto Neuroscience (ANRO), Monopar Therapeutics (MNPR), Leap Therapeutics (LPTX), Rani Therapeutics (RANI), and Assembly Biosciences (ASMB). These companies are all part of the "pharmaceutical preparations" industry. Hookipa Pharma vs. Immunic Context Therapeutics Journey Medical Pyxis Oncology MediciNova Alto Neuroscience Monopar Therapeutics Leap Therapeutics Rani Therapeutics Assembly Biosciences Immunic (NASDAQ:IMUX) and Hookipa Pharma (NASDAQ:HOOK) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their community ranking, dividends, institutional ownership, media sentiment, valuation, earnings, analyst recommendations, risk and profitability. Does the MarketBeat Community believe in IMUX or HOOK? Immunic received 9 more outperform votes than Hookipa Pharma when rated by MarketBeat users. However, 70.54% of users gave Hookipa Pharma an outperform vote while only 64.94% of users gave Immunic an outperform vote. CompanyUnderperformOutperformImmunicOutperform Votes10064.94% Underperform Votes5435.06% Hookipa PharmaOutperform Votes9170.54% Underperform Votes3829.46% Which has more volatility & risk, IMUX or HOOK? Immunic has a beta of 1.89, meaning that its stock price is 89% more volatile than the S&P 500. Comparatively, Hookipa Pharma has a beta of 0.84, meaning that its stock price is 16% less volatile than the S&P 500. Is IMUX or HOOK more profitable? Immunic has a net margin of 0.00% compared to Hookipa Pharma's net margin of -86.74%. Hookipa Pharma's return on equity of -33.31% beat Immunic's return on equity.Company Net Margins Return on Equity Return on Assets ImmunicN/A -169.55% -118.96% Hookipa Pharma -86.74%-33.31%-21.65% Which has stronger valuation & earnings, IMUX or HOOK? Hookipa Pharma has higher revenue and earnings than Immunic. Immunic is trading at a lower price-to-earnings ratio than Hookipa Pharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioImmunicN/AN/A-$93.61M-$1.23-1.14Hookipa Pharma$20.13M1.55-$81.58M-$3.72-0.69 Do analysts recommend IMUX or HOOK? Immunic presently has a consensus target price of $11.80, suggesting a potential upside of 742.86%. Hookipa Pharma has a consensus target price of $38.33, suggesting a potential upside of 1,385.79%. Given Hookipa Pharma's higher possible upside, analysts clearly believe Hookipa Pharma is more favorable than Immunic.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Immunic 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 2 Strong Buy rating(s) 3.29Hookipa Pharma 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do institutionals & insiders believe in IMUX or HOOK? 51.8% of Immunic shares are owned by institutional investors. Comparatively, 63.9% of Hookipa Pharma shares are owned by institutional investors. 3.0% of Immunic shares are owned by insiders. Comparatively, 3.3% of Hookipa Pharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Does the media refer more to IMUX or HOOK? In the previous week, Immunic had 21 more articles in the media than Hookipa Pharma. MarketBeat recorded 24 mentions for Immunic and 3 mentions for Hookipa Pharma. Immunic's average media sentiment score of 0.61 beat Hookipa Pharma's score of 0.34 indicating that Immunic is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immunic 4 Very Positive mention(s) 0 Positive mention(s) 9 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Hookipa Pharma 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryImmunic and Hookipa Pharma tied by winning 9 of the 18 factors compared between the two stocks. Ad Porter & CompanyThis company will win the AI race Rome wasn’t built in a day… But there is another lesser-known type of keystone, one that plays an equally critical role in supporting the most revolutionary technology the world’s ever seen… artificial intelligence. And without it, the entire AI industry would collapse. You must read this new presentation from Porter Stansberry. Get Hookipa Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for HOOK and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart HOOK vs. The Competition Export to ExcelMetricHookipa PharmaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$31.12M$7.05B$5.37B$8.94BDividend YieldN/A7.97%5.33%4.05%P/E Ratio-0.6911.27117.4718.00Price / Sales1.55242.101,426.31155.72Price / CashN/A62.0542.7338.60Price / Book0.4310.647.356.66Net Income-$81.58M$152.36M$118.37M$224.93M7 Day Performance11.21%3.48%3.40%2.50%1 Month Performance-32.81%-1.31%2.49%10.24%1 Year Performance-55.13%31.71%36.16%30.14% Hookipa Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)HOOKHookipa Pharma2.6215 of 5 stars$2.49-3.5%$38.33+1,439.5%-55.1%$30.03M$20.13M-0.6756Short Interest ↑IMUXImmunic3.4728 of 5 stars$1.36+9.3%$11.80+770.8%+16.7%$122.06MN/A0.0070Short Interest ↓Gap UpCNTXContext Therapeutics3.1584 of 5 stars$1.61+5.9%$6.80+322.4%+65.4%$120.75MN/A-1.677Short Interest ↓News CoverageGap DownDERMJourney Medical2.3255 of 5 stars$5.75-0.5%$9.38+63.0%N/A$120.12M$79.18M-6.1590Short Interest ↑PYXSPyxis Oncology2.5056 of 5 stars$2.02+0.5%$10.00+395.1%+22.7%$120.12M$16.15M-1.9360MNOVMediciNova1.9104 of 5 stars$2.40+15.9%$9.00+275.0%+33.7%$117.72M$1M-9.8610Analyst ForecastGap UpHigh Trading VolumeANROAlto Neuroscience2.4017 of 5 stars$4.33-1.8%$20.00+361.9%N/A$116.78M$210,000.000.00N/AMNPRMonopar Therapeutics3.1159 of 5 stars$22.06-2.1%$27.33+23.9%+1,233.9%$116.43MN/A-11.4410News CoverageLPTXLeap Therapeutics1.9942 of 5 stars$2.90-2.7%$7.50+158.6%+23.9%$111.13M$1.50M-1.5440RANIRani Therapeutics2.7359 of 5 stars$1.94-4.2%$11.71+505.4%-18.0%$110.85M$2.72M-1.81110ASMBAssembly Biosciences4.0034 of 5 stars$17.11+0.4%$35.00+104.6%+94.9%$108.82M$7.16M0.00100 Related Companies and Tools Related Companies Immunic Competitors Context Therapeutics Competitors Journey Medical Competitors Pyxis Oncology Competitors MediciNova Competitors Alto Neuroscience Competitors Monopar Therapeutics Competitors Leap Therapeutics Competitors Rani Therapeutics Competitors Assembly Biosciences Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:HOOK) was last updated on 12/3/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredYour bank is lying to you.You might think you have your money in a high-yield savings account, but do you really? The national average A...MyBankTracker | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredIs NVDA a sell? Buy this stock instead before Dec 3After months of speculation that Nvidia was "cooling off..." and "running out of steam..." The company is m...Chaikin Analytics | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Hookipa Pharma Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Hookipa Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
